CIRM Funded Clinical Trials

A Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent β-Thalassemia

Disease Area:
Beta Thalassemia
CIRM Grant:
CLIN2-11031 (Closed)
Award Value:
Trial Sponsor:
Sangamo BioSciences, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Targeted Enrollment:
5 ID:


Sangamo, Inc. is testing genetically engineered blood stem cells for the treatment of beta-thalassemia, a severe form of anemia caused by mutations in the hemoglobin gene. This genetic disorder requires life-long blood transfusions and carries a life expectancy of only 30-50 years. The Sangamo therapy takes a patient’s own blood stem cells and, using a gene-editing technology called zinc finger nuclease (ZFN), provides a functional copy of the hemoglobin gene. These modified cells are given back to the patient which potentially will eliminate the need for chronic transfusions and its associated complications.


Open label, single arm study


Safety and tolerability. Efficacy, change from baseline HbF levels, frequency and volume of RBC transfusions.

News about this clinical trial:

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website